Trovagene announces completion of first dosing cohort of patients treated with PCM-075
Trovagene announced completion of the first dose cohort of PCM-075, a highly-selective Polo-like Kinase 1 Inhibitor, in combination with decitabine, in its Phase 1b/2 clinical trial in patients with Acute Myeloid Leukemia. The combination of PCM-075 and decitabine was well tolerated in all patients. June 15, 2018